Biopharmaceutical company company Halozyme Therapeutics Inc (Nasdaq: HALO) and biotechnology company Skye Bioscience Inc (Nasdaq: SKYE) announced on Monday that the companies entered into a non-exclusive global collaboration and licence agreement in December 2025 to evaluate nimacimab co-formulated with Halozyme's ENHANZE drug delivery technology for the treatment of obesity.

This agreement grants Skye rights to use ENHANZE to develop and potentially commercialise a higher-dose, subcutaneous formulation of nimacimab, enabling delivery of larger injection volumes. Skye will pay development and commercial milestones, while Halozyme will receive mid-single-digit royalties on net sales of ENHANZE-enabled nimacimab for at least 10 years.

Skye plans to initiate a Phase 2b obesity trial in mid-2026 to evaluate nimacimab with ENHANZE, including assessment in combination with a GLP-1 receptor agonist. Nimacimab is currently being studied in a Phase 2a obesity trial as a peripherally acting CB1 negative allosteric modulating antibody.

The collaboration expands Halozyme's ENHANZE platform, which supports subcutaneous delivery of biologics and is licensed to multiple global pharmaceutical partners, while advancing Skye's strategy to develop differentiated metabolic health therapies.